Anavex Life Sciences Announces Publication Titled 'Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients'
Author: Benzinga Newsdesk | September 30, 2025 07:31am